Compare Illinois Tool Works Inc. (ITW) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Zoetis Inc — how do they compare? Illinois Tool Works Inc. trades at $264.31 (market cap $74.38B), while Zoetis Inc trades at $74.11 (market cap $30.20B). The key difference: Illinois Tool Works Inc. is far larger — about 2.5× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 67 Days and Zoetis Inc for 70 Days on average.
| ITW | ZTS | |
|---|---|---|
Market Cap | $74.38B | $30.20B |
Volume | 1,125,477 | 6,175,327 |
Sector | Industrials | Health |
52-Week High | $299.60 | $147.53 |
52-Week Low | $241.07 | $69.09 |
Typical Hold Time | 67 Days | 70 Days |
Enterprise Value | $83.23B | $37.76B |
Dividend Yield | 2.63% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $261.15, down 2.24% on the day, with technical indicators showing bearish momentum as the stock tests support near $261. The company maintains strong fundamentals with a 19.39% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights ITW's dividend increase to $1.72 per share, reinforcing its status as a Dividend King with 59 years of consecutive increases.
The outlook remains mixed with solid profitability offset by bearish technicals. Upside potential exists toward the $276.86 analyst consensus target, but investors face headwinds from weak technical momentum and mixed analyst sentiment where only 21% recommend buying. Key risks include debt levels rising to 55.54% of assets and exposure to cyclical industrial demand.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
